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Current prevention strategies for low-trauma frac-
tures amongst older persons depend on the notions
that fractures are mainly caused by osteoporosis
(pathophysiology), that patients at high risk can be
identified (screening) and that the risk is amenable
to bone-targeted pharmacotherapy (treatment).
However, all these three notions can be disputed.
Pathophysiology. Most fracture patients have fallen,
but actually do not have osteoporosis. A high
likelihood of falling, in turn, is attributable to an
ageing-related decline in physical functioning and
general frailty.
Screening. Currently available fracture risk predic-
tion strategies including bone densitometry and
multifactorial prediction tools are unable to iden-
tify a large proportion of patients who will sustain a
fracture, whereas many of those with a high
fracture risk score will not sustain a fracture.
Treatment. The evidence for the viability of bone-
targeted pharmacotherapy in preventing hip frac-
ture and other clinical fragility fractures is mainly
limited to women aged 65–80 years with osteopo-
rosis, whereas the proof of hip fracture-preventing
efficacy in women over 80 years of age and in men
at all ages is meagre or absent. Further, the antihip
fracture efficacy shown in clinical trials is absent in
real-life studies. Many drugs for the treatment of
osteoporosis have also been associated with
increased risks of serious adverse events. There
are also considerable uncertainties related to the
efficacy of drug therapy in preventing clinical
vertebral fractures, whereas the efficacy for pre-
venting other fractures (relative risk reductions of
20–25%) remains moderate, particularly in terms
of the low absolute risk reduction in fractures with
this treatment.
Keywords: cost-effectiveness, osteoporosis, prediction,
screening, treatment.
Introduction
The World Health Organization introduced opera-
tional diagnostic criteria for osteoporosis in 1994
[1]. Virtually every physician in the world was made
aware of the notion that a decrease of 1 SD in dual-
energy X-ray absorptiometry (DXA)-measured bone
mineral density (BMD) doubles the risk of osteo-
porotic fractures. To manage this challenge of
osteoporosis effectively, diagnosis of osteoporosis
and prevention of related fractures were simplified
for physicians. A widely promoted consensus
depended on the following: (i) osteoporosis (defined
as BMD T-score ≤ 2.5) is the main cause of low-
energy fractures in ageing populations, (ii) bone
densitometry (DXA) reliably identifies individuals
at risk of these fractures and (iii) these fractures
can be cost-effectively prevented by bone-targeted
pharmacotherapy. Accordingly, by the end of the
20th century, many physicians were referring
individuals for BMD testing and prescribing bone-
targeted pharmacotherapy to millions of otherwise
asymptomatic persons, on the basis of a reduced
BMD value alone.
Although there is a wide consensus amongst the
‘mainstay’ regarding the diagnosis, screening and
treatment of osteoporosis, many of the existing
beliefs and concepts are indeed debatable when
placed under proper scientific scrutiny. Prevention
of any medical condition is naturally appealing,
but it is essential to strike the right balance
between benefits and harms with any intervention.
In this review, we demonstrate the most obvious
weaknesses in the prevailing general reasoning
about osteoporosis to highlight the fact that there
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is yet the possibility for improvement in our exist-
ing paradigms for osteoporosis and fracture pre-
vention.
Pathophysiology
To what extent do fracture patients have osteoporosis?
It is well known that the relative risk of a fracture is
at least quadrupled in individuals with DXA-veri-
fied osteoporosis compared to those with normal
BMD [2]. However, a large population-based study
of women aged 65 years or above showed that 85%
of all low-trauma fractures were not attributable to
osteoporosis [3]. Moreover, although BMD is, on
average, associated with risk of fracture [2], the
added discriminatory value of BMD to clinical risk
factors remains modest [4]. In addition, the ability
of BMD to predict hip fractures decreases substan-
tially with increasing age [5]. For example, the
relative risk of hip fracture increased 13-fold from
60 to 80 years of age in both men and women,
whereas the age-related decline in BMD accounted
only for a twofold increased risk [6]. A 44-fold rise
in hip fracture incidence from 55 to 85 years of age
was reported in Swedish women, for which the
impact of age was 11-fold greater than that of BMD
[7].
It is also well established that bone deteriorates
with age, but even a weak bone can survive normal
life without exceptional loading caused by a fall-
induced impact (Fig. 1). Fractures are primarily
caused by falls [8], including the case of vertebral
fractures [9]. Thus, even asking the simple ques-
tion ‘Do you have impaired balance?’ can predict
about 40% of all hip fractures [10], whereas
osteoporosis predicts <30% [3]. With regard to the
distinct fracture incidence between women and
men, the higher incidence in women is attributable
to a higher incidence of falling, not to lower BMD
[11] (Fig. 2).
The risk of falling increases with age and reduced
physical function, and falls are very common
amongst the older population: around one-third
of generally healthy individuals aged 65 or above
and a half of those aged 80 or above will fall at least
once a year. However, only 5% of falls result in any
fracture, and only 1% in a hip fracture [12, 13]. An
important explanation for the increased risk of
falling with older age is muscle weakness. This is
caused not only by decreased muscle mass, but
also by reduced muscle strength and power, as a
consequence of loss of muscle fibres, fatty degen-
eration and fibrotic changes, and a decreased
number of functioning motor units [14]. Muscle
density, not only muscle size, is an important
determinant of future hip fracture risk [15]. The
weight of skeletal muscle comprises ~45% of the
body weight at 21–30 years of age but decreases to
~27% after the age of 70. Over the adult life span,
thigh muscle strength is reduced on average by
40% [16]. It is most likely that the ageing-related
muscle loss and reduced balance contribute to
fracture risk through increased propensity to fall-
ing. This could, at least partly, explain the rela-
tively poor predictive value of bone loss in
identifying those at risk of sustaining fractures in
old age.
Is fracture risk inherited?
Numerous cross-sectional studies have consis-
tently shown a strong heritable component of bone
density, mass and turnover markers [17–19]. How-
ever, the mean heritability of bone loss [20] and
fractures is modest [21, 22], especially in old age
[20, 21], and the heritability of hip fractures
appears to be negligible in older women and men
[21]. There are several important clinical predictors
of fracture risk in the elderly that are either
correlated with or act independently of BMD [23].
Although the search for BMD-specific single nucle-
otide polymorphisms by whole-genome and whole-
exome sequencing has been successful with some
interesting findings [24–26], it has resulted in
identification of only a small fraction of the genetic
variants responsible for regulation of BMD and
susceptibility to fracture. Variation in these genes
accounts for only 6% of the BMD variation, and
even less of the variance in fracture occurrence
[27].
What is the explanation for the apparent discrep-
ancy between the strong heritability of bone traits
in cross-sectional studies and the low heritability
of fracture risk? As noted above, fractures are
mainly caused by falling [8] and the genetic liability
of impaired balance (propensity to falling) is mod-
est [28, 29], at best. Accordingly, it is highly
unlikely that genetic tests will substantially
improve the identification of individuals at high
risk of fractures, especially at older age. The mean
age of hip fracture patients in Europe is about
80 years, and over 75% of all hip fractures occur
amongst individuals older than 75 years [30].
Therefore, given the low heritability of bone loss
and fractures in old age, a likely explanation of the
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Fig. 1 How is structural damage/fractures related to the design of cars/the skeleton? (a) Cars are designed to run on their
wheels. In terms of safety, the design of cars is optimized to keep the driver and passengers intact during collisions from the
typical directions of impact (i.e. the front or rear). However, a similar or even smaller force can cause profound damage if it
comes from an atypical (unforeseen) direction. (b) By analogy, the human skeleton is adapted to bipedal gait and the
resulting habitual locomotive loadings. The skeleton has a high capacity to resist fractures when a trauma leads to
exaggerated forces with an orientation similar to habitual activities. (c) However, in the majority of fractures in older adults,
the trauma caused loading of the skeleton in a direction, rate and magnitude that it was not adapted to. Examples of such
loading incidents are lifting a shopping bag with straight knees (causes vertebral fractures) and a sideways fall directly
onto the hip (the main cause of hip fractures). Adapted from [105].
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low genetic contribution to fractures in large
genomewide association studies is the dominance
of environmental and lifestyle influence on this
complex phenotypic trait.
Are vertebral fractures truly osteoporotic?
Vertebral fractures are commonly considered to be
equally important to those of the hip [31]. However,
the diagnosis of vertebral fracture is quite arbi-
trary; depending on the criteria used for classifying
a change in an X-ray image as a fracture, the
prevalence of vertebral fractures can vary by as
much as 3% to 90% in a given elderly population
[32]. Moreover, a symptomatic vertebral fracture is
rarely ‘spontaneous’ or purely osteoporotic; at least
50% are trauma induced and, in particular, are
due to falling on the buttocks or lifting an object
with straight knees [33–35]. In a recent survey of
vertebral fracture-related emergency department
visits and hospitalizations in the elderly Dutch
population, 83% of vertebral fractures were caused
by a low-energy fall incident [36]. Seemingly benign
physical activities, such as bending or lifting light
objects, produce relatively large loads on the spinal
column (up to 10 times higher compared with
perfect posture) and are capable of fracturing a
vertebra [35, 37] (Fig. 1). Only one-third of the X-
ray changes termed vertebral fractures are symp-
tomatic [38], and the occurrence of vertebral frac-
tures poorly predicts either the existence of back
pain or the functional status of the spine [39, 40].
Although it is commonly argued that vertebral
fractures increase the risk of death, it should be
noted that almost every illness in older adults, by
virtue of the definition of the word ‘illness’ as an
indicator of frailty and weakness, is related to
increased morbidity and mortality, but is seldom a
truly independent risk factor or direct cause of
death. Accordingly, the more relevant question is,
how much of the increased morbidity and mortality
risk associated with vertebral fractures can be
reduced by bone-targeted pharmacotherapy? As
demonstrated herein, there is no evidence that
pharmacotherapy would either provide a clinically
relevant reduction in vertebral fractures or reduce
the related mortality risk (see below).
Do fractures cause excess mortality?
One of the most common arguments for screening
and treatment of osteoporosis is that fractures
cause excess mortality, and therefore, bone-tar-
geted pharmacotherapy could improve survival
[41]. However, evidence supporting this notion is
scarce. Michaelsson et al. [42] recently estimated
the excess mortality associated with a hip fracture
event, controlling for genetic constitution, comor-
bidities, shared familial environmental factors and
lifestyle through following identical twin pairs
discordant for hip fracture. In younger men
(<75 years of age) and in women, irrespective of
age, the excess risk of mortality lasted only during
the first year after the hip fracture event. The
analysis indicated a more long-lasting impact of
hip fracture on subsequent mortality risk only in
men above 75 years of age. This is a strong
indication that the excess mortality after a hip
fracture in women, including duration of the excess
risk, has been overestimated in previous studies
with ordinary designs [43].
The most convincing evidence suggesting that
bone-targeted pharmacotherapy could have an
effect on mortality comes from the HORIZON trial
[44], but the results have been questioned [45]. In a
multivariable analysis of the HORIZON data
adjusted for relevant risk factors (subsequent frac-
Fig. 2 Fractures are primarily due to falling, not osteopo-
rosis. Despite a wide consensus that fractures in adults
are ‘osteoporotic’, evidence indisputably shows that both
hip and vertebral fractures are predominantly traumatic
(caused by an injury).
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ture, change in BMD, infections, cardiovascular
events, arrhythmias and falls), zoledronic acid was
shown to reduce the risk of death by 25% [46].
Although subsequent fractures were associated
with death, they merely explained 8% of the zoled-
ronic acid effect on mortality. Further, adjustment
of the data for acute (nonfatal) events occurring
during follow-up eliminated the death benefit and
established an unexpected association: the protec-
tive effect against arrhythmias was apparent in the
secondary prevention arm of the HORIZON trial,
whereas the incidence of arrhythmias was para-
doxically increased amongst the zoledronic acid-
treated group in the primary prevention arm [46].
Screening
Is BMD an adequate surrogate of individual bone fragility?
Dual-energy X-ray absorptiometry-measured BMD
is strongly correlated with bone strength, and the
relative risk of future fractures is increased by low
BMD or osteoporosis at the group level or in a
population; however, this epidemiological associ-
ation has little clinical relevance for the individ-
ual. Although BMD as a predictor of future
fracture risk is well established and several pro-
spective studies have demonstrated a 1.5- to 2.5-
fold increased risk of fracture for every 1 SD
decrease in BMD [2, 3, 5], BMD alone displays
poor sensitivity in predicting future fractures.
Fewer than one in three hip fractures are attrib-
utable to osteoporosis as defined by total hip BMD
[3]. Thus, sufficiently accurate identification of
fracture-prone individuals is not possible on the
basis of DXA-defined osteoporosis. Moreover, the
ability of BMD to predict hip fractures declines
with age: at 50 years of age, the gradient of risk
(the relative risk per 1 SD decrease in BMD) is
almost four, whereas at the age of 85, it is <2 [5].
Only relative risk values of at least three (corre-
sponding to an area under the receiving operator
characteristic (ROC) curve of about ≥0.8) are
considered to be of clinical relevance for an
individual risk assessment [47].
Further, the DXA measurement inherently
assumes that the scanned body region (e.g. hip or
lumbar spine) comprises only bone and homoge-
neous soft tissue components, but it is clear that
this two-component simplification conflicts with
clinical reality (individual anatomy and body com-
position), resulting in substantial inaccuracy of
individual measurement (Fig. 3a). Despite the fact
that DXA measurements are highly repeatable, the
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Fig. 3 Inherent inaccuracy related to dual-energy X-ray
absorptiometry (DXA)-derived bone mineral density (BMD)
seriously undermines the method. (a) The three body
components of bone mineral, fat and lean soft tissue have
different attenuation coefficients, but DXA employs two
photon energies and can thus only resolve two compo-
nents at a time. Therefore, assumptions are made with
DXA about fat versus lean tissue ratios in the calculation
of BMD. Numerous studies (using both phantoms and
cadaver specimens) have consistently shown that the
magnitude of uncertainty inherent in BMD measurement
can be 1 T-score. (b) To illustrate the difference between
repeatability (precision error) and accuracy (error), the
black cross shows a patient’s result plotted on a typical
DXA scan report. The blue error bars denote the same T-
score result drawn with an error bar indicating the 95%
confidence interval (CI) of 0.2 in the T-score assessment
arising from BMD precision errors. Finally, the same result
is drawn with an error bar indicating the 95% CI of 1.0 in
the T-score assessment arising when accuracy errors and
precision errors are combined. Adapted from [49].
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measurement accuracy is important with regard to
estimated bone strength. The inherent uncertainty
in the BMD measurement can correspond to one T-
score unit to either direction or even more [48–50].
For example, a measured T-score of 2.5 (indicat-
ing osteoporosis) can reflect a true T-score of
between 3.5 (clear osteoporosis) and 1.5 (slight
osteopenia) without any possibility of knowing the
true value for the given individual (Fig. 3b). There-
fore, even large individual changes in BMD, corre-
sponding to those typically observed in clinical
trials, may become irrelevant in terms of fracture
prediction [51].
Are fracture prediction tools useful for an individual risk assessment?
Extensive attempts have been made to identify
high-risk individuals and validate clinical risk
factors, either alone or in combination with BMD
[52]. Similar to the Framingham Risk Score and the
Systematic Coronary Risk Evaluation (SCORE) tool
for predicting an individual’s susceptibility to car-
diovascular disease, these tools (e.g. Garvan,
QFracture and FRAX) typically combine age and
sex with clinical risk factors to provide an estimate
of the 5- or 10-year probability of fracture for an
individual. A clear advantage of fracture prediction
tools is that they provide an estimate of absolute
risk; therefore, even if a 55-year-old woman has
osteoporosis according to DXA, she can still have a
low 10-year risk of fracture that might not indicate
the need for pharmacological treatment.
Of the many available tools, the most widely used is
the FRAX tool [53, 54]; on average, it has 8000
users each day. However, the method has been
criticized for flaws in design and performance [55],
integration of mortality risk [56, 57] and lack of
transparency [58]. Concern has also been
expressed regarding the possibility that these tools
promote overdiagnosis. For example, if the FRAX-
based guidelines were applied, at least 72% of
white women >65 years and 93% of those
>75 years in the USA would be recommended for
drug therapy [59]. For comparison, using the BMD-
based diagnosis of osteoporosis (the current trigger
for drug treatment) the corresponding values for
the EU are 34% and 43%, respectively [30].
Accordingly, using the new National Osteoporosis
Foundation (NOF) guidelines leads to an approxi-
mate doubling of the population for which drug
treatment is recommended. The UK-based National
Osteoporosis Guideline Group (NOGG) guidelines
similarly promote overtreatment, but through a
different mechanism. The NOGG guidelines,
incorporated into the FRAX UK risk tool, advocate
pharmaceutical intervention in individuals whose
estimated fracture risk exceeds that of an individ-
ual of the same age and gender with a prevalent
fragility fracture. Paradoxically, this leads to advo-
cacy of drug treatment for younger individuals
whose absolute risk of fracture is quite low, yet not
for older individuals with higher absolute risk. In
short, FRAX-based screening and subsequent
treatment recommendations promote overdiagno-
sis and misdirection of pharmaceutical resources
(Fig. 4).
Despite these concerns, the use of a ‘high-risk’
identification strategy through fracture risk
assessment tools is also recommended by many
national guidelines, including the FRAX in the
National Osteoporosis Foundation (NOF) [60], the
NOGG [61], Osteoporosis Canada [62] and the UK
National Institute for Health and Care Excellence
(NICE) [63]. Against this background, it is note-
worthy that, to our knowledge, the effect of these
tools in selecting patients for therapy and thus
Fig. 4 Fracture risk prediction tools seem to expand the
treatment thresholds. Whatever the FRAX score for a
given patient, the outcome is almost always the same:
drug therapy.
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improving fracture outcomes has not been
determined to date. Efficacy studies of bone-spe-
cific drugs have largely been undertaken in indi-
viduals with low BMD and previous fractures. It
thus remains uncertain whether the treatment is
as effective when prescribed on the basis of clinical
risk factors and related risk assessment. For
example, the antifracture efficacy of risedronate
could not be demonstrated in women over the age
of 80 who were selected primarily on the basis of
their risk of falling [64]. Neither is there proof from
pharmaceutical interventions that fracture risk
would actually be reduced in those with a high
FRAX score, and whether FRAX in daily practice
improves decision-making and, ultimately,
patient-important outcomes remains unproven
[65]. A recent re-analysis of the data from the large
Fracture Intervention Trial (FIT) showed no signif-
icant association between FRAX score and reduc-
tion in fractures by alendronate [66]. In summary,
the utility of fracture prediction tools for selecting
individuals for bone protective treatment needs to
be confirmed before their widespread use can be
recommended [63].
Treatment
Evidence-based medicine relies to a large extent on
results from RCTs, and many of the problems in
any clinical field are related to judging the extent to
which findings under well-controlled circum-
stances apply to ordinary healthcare settings.
Does the existing evidence justify wide-scale use of bone-targeted
pharmacotherapy?
Benefits of any medical intervention should be
evaluated within the context of the three-step
hierarchy of research evidence originally defined
by Archie Cochrane: efficacy, effectiveness and
cost-effectiveness [67, 68]. Basically, the strategy
to prevent fractures by bone-targeted pharmaco-
therapy would be acceptable if the drugs were
cheap, effective and with low risk of associated
harms. However, it is questionable whether current
medications meet these requirements.
With regard to the costs and effectiveness, even
under the idealized circumstances of efficacy trials,
we found that less than a half of all fractures could
be prevented, whilst the cost of averting one hip
fracture was about £100 000 [68]. By contrast, the
average total cost of treating one hip fracture patient
over the first year after fracture is about £16 000
[68]. Further, despite the fact that the mean age of
hip fracture patients in Europe is about 80 years,
and more than three in four hip fractures occur
amongst individuals older than 75 years [30], this
age group is under-represented in or even absent
from most clinical trials assessing the antihip frac-
ture efficacy of preventive pharmacotherapy. Only
three of the 33 RCTs published so far have included
a sufficient number of women over 75 years of age to
allow analysis of hip fracture incidence [44, 64, 69],
and these three studies did not show significant
efficacy in this age group. Nevertheless, it is com-
monly believed that bisphosphonates can reduce
the relative fracture risk independent of age, so that
the absolute risk reduction would increase with age
or baseline risk [70–72]. Similar to those for other
‘risk diseases’ [73], most osteoporosis guidelines
ignore the lack of evidence in the oldest old
(>80 years of age) and extrapolate the efficacy esti-
matesderived fromyoungeradults to this group. It is
unlikely that the oldest old are comparable to those
in their 60s or 70s in terms of their response to drug
therapy. Finally, osteoporosis is primarily consid-
ered to be a female disease, but about 30–40%of hip
fracturesoccur in elderlymen [30].However, there is
a dire lack of available evidence regarding hip
fracture prevention in men.
Is there any real-life evidence? Whilst confounding
by indication is an obvious risk in these studies,
they actually provide pertinent evidence about the
feasibility of using bone-modifying drugs to prevent
fractures. However, existing real-life data do not
support clear clinically relevant antifracture
(including hip fracture) effects of bisphosphonates
or any other compounds [74–80]. For example, in a
recent Canadian study it was found that despite
greater than fourfold differences between provinces
in prescribing rates of osteoporosis medication in
those aged >55, there were still no between-prov-
ince differences in hip fracture rates in either
gender or any age group [80]. It is arguable that
this effectiveness evidence, despite being based on
40 000–210 000 bisphoshonate users in each
province, lacks adequate power because of heter-
ogenous populations (e.g. in terms of age, socio-
economic status and comorbidities). However, the
clinical relevance of such a marginal fracture
reduction effect, if present, can be disputed.
What about the evidence regarding bone-targeted
pharmacotherapy for prevention of vertebral frac-
tures? It is commonly claimed that treatment of
osteoporosis can reduce vertebral fracture rates by
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30–70%. These are the highest relative risk reduc-
tions achieved by pharmacotherapy for the various
types of fractures amongst older adults. However,
there are considerable uncertainties related to the
quality of evidence on the efficacy of bone-targeted
pharmacotherapy in preventing vertebral fractures
[81]. In a recent systematic review of the entire
bisphosphonates evidence base, the authors iden-
tified 33 sufficiently long (≥1 year) RCTs to assess
the efficacy of bisphosphonates on vertebral frac-
ture incidence amongst postmenopausal women
[81]. However, only two of these trials [82, 83]
reported data on symptomatic vertebral fracture in
the primary prevention setting, showing a 44%
relative reduction [95% confidence interval (CI) 21–
60]. In the secondary prevention setting, a 54%
relative reduction (95% CI 25–72) was observed,
but this was also based on only two trials compar-
ing alendronate to placebo [84, 85]. Of note, the
authors concluded that these efficacy estimates
were likely to be inflated due to substantial attri-
tion bias from incomplete follow-up and outcome
assessment. Moreover, the evidence derived from
efficacy trials (because of carefully selected patient
populations) poorly represents the real-life clinical
setting [68].
Osteoporosis guidelines systematically ignore the
obvious ‘evidence void’ in the RCTs (i.e. no antihip
fracture evidence for women under 65 or above
80 years, or for men in general) and instead
extrapolate efficacy estimates derived from younger
women to their older counterparts and even to
men. Assertions by NOF and NOGG on the ‘cost-
effectiveness’ of bone-targeted pharmacotherapy
are not based on actual trials, but on a computer-
modelled cost-effectiveness analysis [70] which
assumes that bisphosphonates achieve a constant
relative risk reduction for fractures irrespective of
age, sex and baseline risk of fracture (or individual
bisphosphonate). Accordingly, the model predicts a
highly favourable (steadily increasing) absolute
risk reduction with age and baseline risk, which
is hardly the case as outlined above.
Is bone-targeted pharmacotherapy safe?
Bone-targeted pharmacotherapy, like any medica-
tion, is not without associated risks. Considerable
adverse effects of bone-targeted drugs have become
evident. The first reports of atypical femoral shaft
fractures in bisphosphonate users after minimal or
no trauma were published in 2005 [86], but it took
almost 10 years to finally establish the causal
association between oral bisphosphonate use and
atypical femoral fractures [87]. For an association
to be regarded as causative, it has to be strong,
show a dose- or time-dependent relation, cease
with the end of treatment and have a plausible
pathophysiological explanation. In the case of
bisphosphonate use and atypical fractures, all
these requirements are fulfilled. Comorbidities
and concomitant use of other drugs do not seem
to explain the association. Genetic predisposition
for atypical fractures is, however, still a possible
explanatory factor. Nonetheless, the association
between bisphosphonate treatment and atypical
femoral fractures has now been shown in several
observational studies with similar methodologies.
Conflicting results in some studies are largely
attributable to differences in the radiographic
definition of atypical fractures [88, 89] and lack of
statistical power [90]. Despite the strong and
apparent causative association between bis-
phosphonates and atypical fractures, about 20%
of patients with an accurately defined atypical
femoral fracture have never been treated with
bisphosphonates. In this context, the long-dis-
puted [91] relation between smoking and lung
cancer is pertinent. Smoking, the main established
cause of small cell and nonsmall cell lung cancer,
contributes to 80% and 90% of lung cancer deaths
in women and men, respectively [92], whilst the
remaining 10–20% of cases are not attributable to
smoking. Amongst heavy long-term smokers, men
are 23 times more likely to develop lung cancer and
women are 13 times more likely, compared to never
smokers [92]. Nonetheless, RCTs of smoking ces-
sation have shown no benefit on mortality [93]. The
current evidence for the link between bisphospho-
nates and atypical fractures has striking similari-
ties although nowadays the fact that smoking is a
cause of lung cancer and premature death would
not be disputed.
According to the most recent data, the relative risk
of atypical fracture after a few years of bisphosph-
onate use (RR >100) is higher than that for lung
cancer amongst smokers, although the absolute
risk is modest: 11 atypical femoral fractures per
year amongst 10 000 users of bisphosphonates
[94]. One atypical femoral fracture will occur for
about 300 patients treated for 3 years. Based on
these real-life estimates of risks related to the use
of bone-targeted pharmacotherapy, it has been
argued that the off-label use of these drugs might
reverse the fracture-preventive benefit, leading
instead to a dominance of adverse events, when
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the net effect on the entire population is considered
[95].
Conclusion
Is osteoporosis different from other risk diseases?
Advocates of the prevailing osteoporosis-based
prevention and treatment strategy for fractures
argue that BMD predicts fracture risk as accu-
rately as blood pressure predicts stroke and con-
siderably better than serum cholesterol predicts
coronary artery disease [2, 96, 97]. This is true.
However, it is rarely noted that this strategy also
leads to labelling the majority of otherwise asymp-
tomatic older people as sick and subjecting them to
long-term medication to prevent relatively rare
morbid events (Fig. 4).
A disease label can have both positive and negative
consequences [98, 99], but, as stated by Spence,
‘labels are sticky and peeling them off can be a
messy business’ [100]. In a survey of a random
sample of 261 women who had undergone bone
densitometry, Rubin and Cummings [101]
assessed how the results of bone densitometry
affected the women’s decisions about measures to
prevent fractures. They also determined whether
labelling women as having below-normal BMD has
adverse effects. Compared with women with nor-
mal results, those with below-normal BMD values
were much more likely to take measures to prevent
fractures, to start hormone therapy and to take
precautions to avoid falling. All this can be consid-
ered beneficial for health. Unfortunately, because
the fear of falling was more prevalent amongst
those with low BMD values, they also limited their
activities to avoid falling.
We wonder whether it is justified to screen and
then possibly treat asymptomatic individuals with
potentially ‘increased fracture risk’ whilst knowing
that the treatment is likely to be futile as the
probability of not sustaining a fracture is many
times greater than the probability of sustaining a
fracture.
Overmedicalized fracture prevention
What might be a more logical or appropriate use of
currently available screening options or therapeu-
tic agents for prevention of fractures? The conclu-
sion of a classic paper published almost 25 years
ago entitled ‘Strategies for prevention of osteopo-
rosis and hip fractures’ [102] is still pertinent. The
message can be succinctly summarized as follows:
despite the burden of illness related to hip frac-
tures, the main ways to prevent these fractures
have not changed in nearly 25 years: stop smok-
ing, be active and eat well. This advice is appro-
priate for anyone whether or not they are worried
about osteoporosis and has advantages for the
entire human body, including the brain, heart,
skin and bones.
The prevailing pharmacological fracture prevention
strategy is conceptually appealing because it is
relatively simple. However, key facts about hip
fracture patients shouldbenoted: they are generally
old (mean age around 80 years) and undeniably
frail. Regrettably, bone-targeted pharmacotherapy
has, at best, minimal effect on the incidence of
fractures and on fracture-related mortality [45] and
is associated with adverse effects. Unnecessary
labelling of asymptomatic individuals also has
adverse consequences, and the strategy squanders
limited healthcare resources.
Given all this, should ‘osteoporosis’ be added to a
long list of diagnoses [103, 104] for which doing
less, or even nothing, is better than our contem-
porary practice?
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